Relamorelin Beneficial in Adults With Diabetic Gastroparesis

This article originally appeared here.
Share this content:
Relamorelin Beneficial in Adults With Diabetic Gastroparesis
Relamorelin Beneficial in Adults With Diabetic Gastroparesis

THURSDAY, July 7, 2016 (HealthDay News) -- For adults with diabetic gastroparesis, relamorelin reduces vomiting frequency and severity and accelerates gastric emptying, according to a study published in the July issue of Gastroenterology.

Anthony Lembo, M.D., from Beth Israel Deaconess Medical Center in Boston, and colleagues conducted a double-blind trial involving 204 patients with diabetic gastroparesis with moderate to severe symptoms and delayed gastric emptying. Patients were randomized to groups receiving placebo or subcutaneous relamorelin 10 µg once or twice per day.

The researchers found that compared with placebo, twice-daily relamorelin correlated with significantly accelerated gastric emptying and reduced vomiting frequency (by about 60 percent) and severity. Relamorelin did not improve other gastrointestinal symptoms, such as abdominal pain and satiety, compared with placebo. A total of 58.3 percent of patients had baseline vomiting; for these patients, twice-daily relamorelin reduced the half-time of gastric emptying and vomiting, nausea, abdominal pain, bloating, and early satiety relative to placebo. There were no overall safety concerns.

"The results from this randomized, double-blind, phase 2 trial continue to support that relamorelin is a potent prokinetic agent, as evidenced by significant effects on gastric emptying and important clinically relevant and statistically significant effects on the objective symptom of vomiting," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Rhythm Pharmaceuticals, which funded the study.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Recent Decline in Prescription Opioid Use Among U.S. Teens

Recent Decline in Prescription Opioid Use Among U.S. ...

Lifetime prevalence of use peaked in 1989, 2002, and remained stable until decline in 2013 to 2015

Treatment Seeking Low Among Teens With Eating Disorders

Treatment Seeking Low Among Teens With Eating Disorders

Those with counter-stereotypic presentation even less likely to seek treatment

Optical Clearing Agent Ups No. of Laser Passes in Tattoo Removal

Optical Clearing Agent Ups No. of Laser Passes ...

Findings based on number of laser passes during a five-minute tattoo removal session

is free, fast, and customized just for you!

Already a member?

Sign In Now »